Litigation
In re Pomalyst (pomalidomide) Antitrust Litigation
dismissed; leave to amend soughtAuto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
Patents at issue (3)
Defendants (2)
Summary
Putative class actions filed beginning September 2023 against Celgene, Bristol Myers Squibb, and individuals alleging antitrust, consumer-protection, and unjust-enrichment claims relating to the Pomalyst patents, including the '647 family. In March 2025 the court dismissed the complaints, and plaintiffs sought leave to amend.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).